US researchers develop algorithm test to identify aggressive ovarian cancers
Ovarian high-grade serous carcinoma is the most common form of aggressive ovarian cancer
Read More
Tag: Ovarian Cancer
NICE recommends more genetic testing for links to ovarian cancer
Around 340,000 to 444,000 people in the UK carry one of nine pathogenic gene variants
Read More
Takeda and ImmunoGen partner to develop and commercialise Elahere in Japan
ImmunoGen is expected to receive an upfront payment from Takeda plus additional payment
Read More
Promising early results for new ovarian cancer drug combo
Drug combination could offer a new option for treatment-resistant advanced ovarian cancer
Read More
NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
Read More
NICE backs GSK’s Zejula in advanced ovarian cancer
Zejula has been recommended for use in newly diagnosed ovarian cancer patients
Read More
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
Blood test more predictive of ovarian cancer than ‘previously thought’
Findings come from new research funded by Cancer Research UK and NIHR
Read More
Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
GSK books 19% sales growth for first quarter
Pharmaceutical sales were up 6% on the year ago period
Read More
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
Read More
Success for GSK’s Zejula in ovarian cancer
The drug was found to demonstrate significant improvement in progression free survival for women regardless of their biomarker status.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
